What Collegium Pharmaceutical, Inc does.

Our mission is to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. We have developed, licensed, and acquired a portfolio of meaningfully differentiated products for use in the treatment of attention deficit hyperactivity disorder (“ADHD”) and moderate to severe pain. We commercialize our products, consisting of Jornay PM, Belbuca, Xtampza ER, Nucynta ER and Nucynta IR (collectively the “Nucynta Products”), and Symproic, in the United States.

On September 3, 2024, we acquired Ironshore, which had developed and obtained commercial approval to market Jornay PM in the United States.

Jornay PM is a central nervous system (“CNS”) stimulant prescription medicine that contains methylphenidate HCl, a Schedule II methylphenidate, which was approved by the U.S. Food and Drug Administration (“FDA”) in August 2018 for the treatment of ADHD in people six years of age and older and currently the only FDA-approved stimulant medication that is dosed in the evening.

Revenue and profit, by fiscal year.

More on COLL.

• Collegium Pharmaceutical, Inc summary
• Collegium Pharmaceutical, Inc financial statements
• Collegium Pharmaceutical, Inc key metrics
• Collegium Pharmaceutical, Inc health scores and style box
• Collegium Pharmaceutical, Inc earnings
• Collegium Pharmaceutical, Inc dividends
• Collegium Pharmaceutical, Inc valuation
• Collegium Pharmaceutical, Inc ownership and insiders
• Collegium Pharmaceutical, Inc peers

Figures from Collegium Pharmaceutical, Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.